AstraZeneca PLC
AZNEquityAI Summary
Updated 6h ago
AstraZeneca PLC (AZN) is in a mixed position
AstraZeneca PLC (AZN) is in a mixed position. Some indicators are above average, others below, but nothing is at an extreme that demands attention. For reference: Flow Score 41/100, Trend & Momentum Score 28/100.
Market Positioning
What's Happening
AZN beat Q1 earnings expectations on April 29
AstraZeneca reported first-quarter 2026 EPS of $2.58 on April 29, topping the $1.53 consensus estimate cited by Public.com by 68.63%. The surprise matters because it signals the underlying earnings base is still running ahead of sell-side expectations, which can support valuation confidence even without a major rerating immediately following the print.
The Bigger Picture
AZN is trading on earnings durability, not just pipeline headlines
Earnings power still drives sentiment
AstraZeneca’s April 29 Q1 beat showed the market that earnings delivery remains the core support for the stock. With HL.co.uk showing 2026 projected EPS of $7.57 versus $6.14 in 2025, investors are clearly looking for continued expansion rather than a one-off quarter. The non-obvious point is that consistent execution can matter more than headline pipeline news when the stock is already widely followed.
Upcoming Catalysts
Updated 3d agoAstraZeneca’s next earnings print is the main near-term catalyst. Investors will focus on whether the company can extend the April earnings beat and confirm that 2026 EPS expectations still have room to rise.
Management commentary on product momentum, margin discipline, and capital allocation will matter as much as the reported numbers. Any shift in full-year guidance or tone on pipeline conversion could move expectations for the second half of 2026.
AstraZeneca’s prior ex-dividend date listed by HL.co.uk was 19 February 2026, so investors will be watching for the next dividend-related schedule update around the usual late-summer timing window. For income-oriented holders, the exact declaration and ex-date can help frame short-term demand for the shares.
Technical Analysis
Market Positioning
Where does this asset sit across four dimensions? Extension (how stretched price is vs its own history), Momentum (RSI, MACD, rate of change), Flow (volume and money flow), and Volatility (how quiet or active). Each bar shows a 0–100 percentile compared to the last year of data. Key levels show the nearest demand and supply zones from our confluence analysis.
Key Levels
Looking at the full picture for AstraZeneca PLC (AZN): extension is deeply below average — at historically low levels (14th percentile), momentum is slightly below average (31st percentile), flow is below average (28th percentile), volatility is slightly below average (37th percentile).
Where is money flowing?
Trend
Is momentum building or fading?
What is the relative strength?
How extended is this move?
Where are the key levels?
What risk am I taking?
Conclusion
AstraZeneca PLC (AZN) is in a mixed position. Some indicators are above average, others below, but nothing is at an extreme level that defines the current setup strongly in either direction. These readings update daily. Flipside shows what is happening now, grounded in the data — not what will happen next.
Your portfolio. Your context. Smarter decisions.
Connect your holdings and let the Flipside Agent analyze market changes through the lens of your portfolio.
Personalized insights based on your actual holdings
Major market movements delivered to your inbox
Track the assets that matter most to you
No credit card required